Drug Discovery Processes

Application note: A novel way to expedite antibody discovery

15 June 2018 | By IntelliCyt Corporation

Analyse isotype titer and cell health in one assay...

Streamlining drug discovery assays for cancer and cardiovascular disease

11 June 2018 | By PerkinElmer

For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.

Expert view: Rising growth of the global high‑content screening software and services market

11 June 2018 | By Jeff McMillan (Senior Product Manager Imaging at Molecular Devices)

The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.

Transforming translational research: CANscript^TM – a better predictive model for oncology

8 June 2018 | By Mark Paris

This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.

Automated assessment of liver and cardiac toxicities in lead optimisation

8 June 2018 | By Tecan

This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.

Expert view: Overcoming the problems of working with human primary hepatocytes

7 June 2018 | By Liz Quinn (Associate Director - Stem Cells Marketing at Takara Bio USA)

Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.

Application note: Cellartis® Power™ Primary HEP Medium – extend functionality of your primary hepatocytes to 4 weeks

7 June 2018 | By Takara Bio

Human primary hepatocytes (hphep cells) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, safety assessment of drug candidates, and disease modeling.

Scientists create ‘genetic atlas’ of proteins in human blood

7 June 2018 | By Drug Target Review

Researchers have created the first detailed genetic map of human proteins...

Expert view: Biological therapeutics are becoming more popular, here are the reasons

7 June 2018 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)

For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.

Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening

6 June 2018 | By Sesha Tekur (Key Accounts Manage/Field Application Specialist at Thermo Fisher Scientific)

For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.

Expert view: Preparing drug discovery for smart screening era

5 June 2018 | By Philip Spencer (AstraZeneca)

Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.

Expert view: High-throughput binding kinetic analysis – is it the new frontier in drug discovery?

5 June 2018 | By Tobias Pusterla (International Marketing Manager at BMG Labtech)

Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.

Tecan

Supporting the progression of phenotypic hits with bioactivity profiling

4 June 2018 | By Drug Target Review

Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.

Tech note: Long term live cell imaging in a high-content system

29 May 2018 | By PerkinElmer

How to perform successful long term live cell imaging in a high-content analysis system.